Bristol-Myers Squibb Pharmaceuticals Group
Executive Summary
President-Central and Eastern Europe Joachim von Roy named president-Europe. He will continue to be based in Munich, reporting to Pharmaceutical Group President Kenneth Weg. In addition, von Roy assumes worldwide responsibility for BMS' cardiovascular product planning and becomes a member of group's operating committee. Samuel Hamad, president of the intercontinental division of the BMS Pharmaceutical Group, has assumed responsibility for Latin America and Japan in addition to his current responsibilities of Asia, Australia/New Zealand, Canada, the Middle East and Africa.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth